Ziopharm Oncology Inc. (NASDAQ:ZIOP)’s share price rose 4.8% during trading on Tuesday . The stock traded as high as $6.12 and last traded at $5.93, with a volume of 1,807,898 shares trading hands. The stock had previously closed at $5.66.

ZIOP has been the topic of several research reports. Wells Fargo & Co. raised Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a research report on Wednesday, August 10th. Zacks Investment Research raised Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a research report on Tuesday, August 16th. Griffin Securities reaffirmed a “buy” rating and issued a $21.00 target price on shares of Ziopharm Oncology in a research report on Monday, August 15th. Raymond James Financial Inc. initiated coverage on Ziopharm Oncology in a research report on Thursday, June 2nd. They issued a “market perform” rating on the stock. Finally, Mizuho reaffirmed a “neutral” rating and issued a $5.00 target price (down previously from $7.00) on shares of Ziopharm Oncology in a research report on Monday, July 18th. Four analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Ziopharm Oncology presently has a consensus rating of “Buy” and a consensus target price of $9.75.

The stock has a 50 day moving average price of $5.32 and a 200 day moving average price of $6.57. The company’s market cap is $763.40 million.

Ziopharm Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.90. The company had revenue of $1.70 million for the quarter, compared to analyst estimates of $1.52 million. Ziopharm Oncology had a negative net margin of 2,292.26% and a negative return on equity of 100.01%. Ziopharm Oncology’s revenue for the quarter was up 525.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.11) EPS. On average, analysts forecast that Ziopharm Oncology Inc. will post ($1.34) EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. Fox Run Management L.L.C. purchased a new position in Ziopharm Oncology during the second quarter valued at approximately $133,000. Creative Planning boosted its position in Ziopharm Oncology by 185.1% in the second quarter. Creative Planning now owns 30,864 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 20,040 shares in the last quarter. Royal Bank of Canada boosted its position in Ziopharm Oncology by 6.4% in the first quarter. Royal Bank of Canada now owns 16,189 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 974 shares in the last quarter. LPL Financial LLC boosted its position in Ziopharm Oncology by 60.3% in the first quarter. LPL Financial LLC now owns 40,210 shares of the biotechnology company’s stock valued at $311,000 after buying an additional 15,132 shares in the last quarter. Finally, A.R.T. Advisors LLC purchased a new position in Ziopharm Oncology during the first quarter valued at approximately $1,732,000. 44.95% of the stock is currently owned by hedge funds and other institutional investors.

Ziopharm Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

5 Day Chart for NASDAQ:ZIOP

Receive News & Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.